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Patients with gout have short telomeres compared
with healthy participants: association of telomere
length with ﬂare frequency and cardiovascular
disease in gout
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P G Shiels,5 N Dalbeth,6 L K Stamp,7 T R Merriman,8 M Janssen,4
T R D J Radstake,1,2 J CA Broen1,2
ABSTRACT
Aim and background Chronic inﬂammation
associates with increased senescence, which is a strong
predictor for cardiovascular disease. We hypothesised
that inﬂammation accelerates senescence and thereby
enhances the risk of cardiovascular disease in gout.
Methods We assessed replicative senescence by
quantifying telomere length (TL) in a discovery cohort of
145 Dutch patients with gout and 273 healthy
individuals and validated our results in 474 patients with
gout and 293 healthy participants from New Zealand.
Subsequently, we investigated the effect of
cardiovascular disease on TL of all participants. Also,
we measured TL of CD4+ and CD8+ T lymphocytes,
B lymphocytes, monocytes, natural killer cells and
plasmacytoid dendritic cells. Additionally, we assessed
the potential temporal difference in TL and telomerase
activity.
Results TL in PBMCs of healthy donors decreased over
time, reﬂecting normal ageing. Patients with gout
demonstrated shorter telomeres (p=0.001, R2=0.01873).
In fact, the extent of telomere erosion in patients with gout
was higher at any age compared with healthy counterparts
at any age (p<0.0001, R2=0.02847). Patients with gout
with cardiovascular disease had the shortest telomeres and
TL was an independent risk factor for cardiovascular
disease in patients with gout (p=0.001). TL was inversely
associated with the number of gouty ﬂares (p=0.005).
Conclusions Patients with gout have shorter telomeres
than healthy participants, reﬂecting increased cellular
senescence. Telomere shortening was associated with the
number of ﬂares and with cardiovascular disease in people
with gout.
INTRODUCTION
Gout is a rheumatic disease characterised by depos-
ition of monosodium urate crystals in and around
the joints, associated with elevated serum urate
levels. Gout is the most common inﬂammatory
arthritis in men older than 40 years and it affects
1–5% of adults in the Western populations.1–5
Patients experience recurrent episodes of acute
joint inﬂammation and, in the presence of persist-
ent hyperuricaemia, may also develop chronic joint
inﬂammation. We recently demonstrated that
patients with gout display high levels of
inﬂammatory mediators such as interleukin (IL)-8
even though these patients did not have clinically
apparent inﬂammatory disease at the time of
sample collection.6
Chronic and recurrent inﬂammation activates the
immune system, elevating the demand for immune
cells, damaging tissues and forcing cell replication.
This can ultimately eventuate a state of replicative sen-
escence in most cells. Replicative senescence is when
cells can no longer divide to form new cells. These
senescent cells secrete pro-inﬂammatory markers such
as IL-6 and IL-1a.7 The most commonly used marker
for replicative senescence is telomere length (TL).
Telomeres function as a non-coding protective end
region of chromosomes. Due to the DNA end-
replication inefﬁciency of polymerases, chromosomes
shorten every cell division. After a certain number of
divisions, the threshold of attrition is reached, cell-
cycle arrest occurs and eventuates the senescent state.
Telomeres therefore are indicative of the number of
divisions the cell lineage has undergone and are a
measure of replicative senescence.
Since recurrent and chronic inﬂammation leads
to replicative senescence, which in turn contributes
to a pro-inﬂammatory environment, measuring rep-
licative senescence by TL has been a subject of scru-
tiny in inﬂammatory diseases.8 Telomere shortening
has been repeatedly associated with multiple
inﬂammatory diseases. Previously, TL has been
associated with lifespan, although this remains con-
troversial, and with cardiovascular disease.9 The
latter association has been recently substantiated in
a large meta-analysis including >50 000 indivi-
duals.10 This study showed a signiﬁcantly increased
relative risk for developing cardiovascular and cere-
brovascular disease in the tertile of the population
with the shortest telomeres. Causality between sen-
escence and cardiovascular diseases is supported by
the presence of a high number of senescent cells in
atherosclerotic plaques, enhancing inﬂammation
and decreasing recovery potential. Endothelial
cells, vascular smooth muscle cells (VSMCs) and
immune cells are involved. The reduced prolifera-
tive capacity of endothelial cells and VSMCs,
together with the pro-inﬂammatory environment,
leads to plaque instability, preluding vascular
events.11–13
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Gout is often accompanied by cardiovascular comorbid condi-
tions including myocardial infarction (MI) and cerebrovascular
events, which lead to an increased morbidity and decreased life
span.14 15 Gout is also associated with metabolic syndrome, dia-
betes and renal failure, which in turn are predictors for cardio-
vascular disease. However, patients with gout remain at higher
risk for developing cardiovascular disease after correction for
these variables.16
We hypothesise that chronic and recurrent acute inﬂammation
in gout accelerates replicative senescence, increasing the risk of
cardiovascular disease. That is, patients with gout with the
highest burden of replicative senescence will also have the
highest burden of cardiovascular disease. To test our hypothesis,
we investigated the most studied hallmark of replicative senes-
cence, TL of PBMCs in two independent cohorts consisting of
patients with gout and healthy individuals, both with and
without cardiovascular disease. Also, we investigated telomere
dynamics in various immune cell subsets, scrutinised TL in a
follow-up cohort and quantiﬁed human telomerase reverse tran-
scriptase (hTERT) (encoding human telomere reverse transcript-
ase) gene expression.
METHODS
Discovery cohort and validation cohort
In our discovery cohort, we compared TL of PBMCs in 145
patients with gout with 273 Dutch participants (see online
supplementary table S1). In our validation cohort, we assessed
TL in PBMCs collected from 474 Caucasian patients with gout
and 293 healthy participants participating from New Zealand
(see online supplementary table S1).
This study was performed according to the guidelines of the
Declaration of Helsinki and meets the ethical approval of the
Ethical and Review committee of the University Medical Centre
of Utrecht, Rijnstate Hospital, in Arnhem (both the
Netherlands) and the Multi-Region Ethics Committee in New
Zealand. All the participants in this study gave their informed
consent to participate.
Isolation of mononuclear immune cell subsets
Mononuclear cell subsets were sorted from total PBMCs isolated
by Ficoll (Ficoll-Paque Plus, GE Healthcare) from peripheral
blood of 10 Dutch patients with gout and 11 healthy participants
(see online supplementary table S3). Sorting the mononuclear
cell subsets was performed using ﬂuorescence-activated cell
sorting (FACSAria_III, BD Biosciences) to separate the cells
according to the expression of cellular surface molecules; CD3+/
CD56−/CD4+ for T helper lymphocytes, CD3+/CD56−/CD8+
for cytotoxic T lymphocytes, CD19+/CD20+ for B lymphocytes,
CD14+ monocytes, CD3−/CD56+ natural killer (NK) cells and
CD123 (IL3RA)+/ CD304 (BDCA4)+ plasmacytoid dendritic
cells (pDCs).
TL measurements
DNA of PBMCs was extracted using a standard salting-out
protocol. Absolute TL quantiﬁcation17 modiﬁed with synthetic
standards as described by O’Connell et al18 was performed
using the quantitative PCR method.
hTERT gene expression
hTERT gene expression level was quantiﬁed using synthesised
cDNA (Biorad iScript kit) from RNA that was extracted from
the PBMCs. Patients with gout (N=64) and healthy participants
(N=89) from the Dutch cohort were randomly chosen.
Quantstudio QPCR apparatus with TaqMan assay (Applied
Biosystems) were used to perform QPCR under conditions as
speciﬁed by the manufacturer. To normalise the hTERT gene
expression, the housekeeping GUSB and GAPDH genes were
included. A similar method was used to assess hTERT gene
expression in 10 patients with gout and 11 healthy participants
immune cell subtypes separately.
Statistical analyses
For statistical analysis, IBM SPSS Statistics V.23 (SPSS, Chicago,
Illinois 60606 USA) and GraphPad Prism V.6 (GraphPad
Software, San Diego, California, USA) applications were
applied. TL (in kilobase pairs) of patients with gout and healthy
participants were log-transformed to normalise the distribution.
A two-tailed t-test was used when appropriate with Welch’s cor-
rection for comparing the unequal variances between the
groups. Three independent linear regression models were
applied to separately estimate (a) the interpolation between TL
and age, gender, smoking, cardiovascular disease, heart failure,
stroke (non-fatal), MI (non-fatal), angina pectoris, systolic and
diastolic blood pressure, body mass index (BMI) (kg/m2), serum
UA level (mmol/L) and creatinine level (mmol/L) in patients and
healthy individuals; (b) the association between TL and the pres-
ence of cardiovascular events (heart failure, stroke (non-fatal),
MI (non-fatal), angina pectoris and age) severally in individuals
with gout; and (C) the relation between TL and gout hallmarks
including attack frequency, age at the ﬁrst attack, disease dur-
ation, serum UA level (mmol/L) and creatinine level (mmol/L)
severally in patients group (table 2).
In addition, the difference in TL between gout patients with
or without cardiovascular events (a) and separately the associ-
ation between ﬂare frequency and cardiovascular events (angina
pectoris, heart failure, MI (non-fatal) and stroke (non-fatal)) (b)
is represented in online supplementary table S4. Univariate ana-
lysis was performed to examine the effect of variables such as
gender, age, smoking, BMI and creatinine levels on TL (see
online supplementary table 5). Where appropriate, two-tailed
Pearson’s or Spearman’s bivariate correlations were applied to
assess the correlation between the variables (p<0.05). The
Bonferroni correction was applied to account for multiple
testing.
RESULTS
Demographics
Baseline characteristics of participants from the Netherlands and
New Zealand are summarised in table 1.
PBMCs from patients with gout have shorter telomeres
compared with their healthy counterparts in two unrelated
cohorts
Within our Dutch discovery cohort, we analysed the TL of
PBMCs of 273 healthy participants and 145 patients with gout
and correlated the results with their age in year. The TL in
patients with gout was signiﬁcantly shorter than healthy partici-
pants (see online supplementary table S1). In patients with gout,
linear regression analyses demonstrated no association between
age and TL (p>0.05, R2=0.002853) (telomere shortenin-
g=0.002082*age+4.01). This was in contrast to the signiﬁcant
inverse/negative correlation between TL and age in healthy par-
ticipants (p<0.0001, R2=0.3721) (telomere shortening=
−0.02180*age+5.31) (see online supplementary ﬁgure S1).
Next our results in the independent cohort of New Zealand
Caucasian showed that TL was signiﬁcantly shorter in patients
with gout (N=474) compared with healthy participants
(N=293) (see online supplementary table S2). Moreover, we
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found a negative association between TL and age in patients
with gout (p=0.0014, R2=0.02276) (telomere erosion=
−0.004926*age+3.51). In healthy participants, we found a
negative association with age (p<0.0001, R2=0.111) (telomere
erosion=−0.01089*age+3.94) (see online supplementary table
S2 and ﬁgure S2).
Given the similarities in TL of PBMCs in both the discovery and
replication cohort, we pooled the data (ﬁgure 1). When corrected
for age, patients with gout have signiﬁcantly shorter telomeres in
PBMCs compared with healthy participants (p<0.0001). TL cor-
relates negatively with age in patients with gout (p=0.0010,
R2=0.01873) (TL=−0.006084*X+3.79). Similarly, PBMCs TL
in healthy participants were inversely correlated with age
(p<0.0001, R2=0.02847) (TL=−0.006349*X+3.99).
Finally, we had access to follow-up data on TL from nine
patients with gout involved in the Dutch cohort of whom
88.90% were male 46–87 years old with a median age of
63 years. The time period between the inclusion date and the
follow-up at the second time point was from 1 to 11 months
with an average of 4.33 months. There was no (p=0.34) change
in TL of the same patients with gout measured at two different
time points (T1=4.20 kbp and T2=4.29 kbp).
Gout and cardiovascular disease have an independent
and cumulative effect on telomere attrition
Since gout is strongly associated with cardiovascular disease,
and cardiovascular disease has been associated with shorter telo-
meres, we investigated their separate effects. We included both
patients with gout and participants with chronic heart disease,
non-fatal MI, non-fatal stroke and angina pectoris (ﬁgure 2).
Consistent with previous reports, healthy participants without
cardiovascular disease had longer telomeres (p=0.04) compared
with healthy participants with cardiovascular disorders. The
presence of cardiovascular disease in patients with gout resulted
in signiﬁcantly shorter telomeres (p=0.0001) compared with
individuals with gout only. Moreover, TL in patients with gout
without cardiovascular disease was shorter (p=0.0037) com-
pared with matched healthy individuals (ﬁgure 2).
Consequently, both gout and cardiovascular disease eventuated
even shorter telomeres compared with healthy participants
(p=0.005). Patients with cardiovascular disease concomitant
with gout demonstrated shorter telomeres (p<0.0001) com-
pared with healthy individuals without any comorbidities.
In the linear regression model involving both patients with
gout and healthy individuals, gout (p=0.008), cardiovascular
disease (p=0.023) and heart failure (p=0.01) were independ-
ently inﬂuencing TL (table 2A). Of note, although all the con-
tinuous variables mentioned in table 2 were included in this
model, gout, cardiovascular disease and heart failure remained
in the model as signiﬁcantly associated with TL. Moreover, in a
linear regression model, cardiovascular disease (p=0.001) and
MI (p=0.016) inﬂuenced telomere attrition in the gout popula-
tion (table 2B). Additionally, in a separately performed inde-
pendent linear regression model, the age at the ﬁrst gout event
(p=0.04), frequency of gouty ﬂares (p=0.005) and the disease
duration (p=0.035) were the most signiﬁcant hallmarks of gout
associating with shorter telomeres (table 2C).
Furthermore, analysis revealed signiﬁcantly shorter telomeres
in patients with gout and cardiovascular events compared with
gout patients without cardiovascular events (see online
supplementary table S4A). According to the linear regression
model, however, there was no association between the ﬂare fre-
quency and cardiovascular events in patients with gout (see
online supplementary table S4B).
Table 1 Baseline characteristics of Dutch and New Zealand patients and healthy participants
Gout (n=619) Healthy participants (n=566) p Value
Male, n (%) 489 (79.00) 398 (70.32) 0.247
Age (mean±SD) 62.8±14.15 59.60±13.67 0.0001
Age at the first flare (mean±SD) 51.12±16.75 – –
Disease duration (year) (mean±SD) 12.90±12.28 – –
Colchicine (yes), n (%) 254 (50.50) 1 (0.17) 0.247
Non-steroidal anti-inflammatory drug (yes), n (%) 353 (75.50) 2 (0.35) 0.433
Allopurinol (yes), n (%) (mean 200 mg/day) 337 (67.10) 1 (0.17) 0.0001
Corticosteroids (yes) n (%) 197 (40.20) 1 (0.17) 0.643
CVD (yes/no) n (%) 270 (43.62) 43 (7.59) 0.0001
Diabetes (type 2) (yes), n (%) 87 (14.02) 19 (3.36) 0.0001
Stroke (yes/no), n (%) 43 (6.95) 67 (11.83) 0.0001
Myocardial infarction (non-fatal) (yes), n (%) 70 (8.60) 66 (11.60) 0.054
Heart failure (yes), n (%) 70 (11.31) 64 (11.31) 0.270
Angina pectoris (yes), n (%) 37 (5.98) 7 (1.24) 0.0001
Creatinine level (mmol/L) (mean±SD) 105.73 (±39.38) 93.44 (±30.29) 0.0001
Body mass index (kg/m2) (mean±SD) 29.73 (±5.60) 28 (±6.37) 0.0001
Smoking (yes) n (%) 51 (8.24) 5 (0.90) 0.0001
Serum urate (mmol/L) (mean±SD) 0.43 (±0.13) 0.35 (±0.10) 0.0001
Total number of flares per year (mean±SD) 8.75±(12.67) – –
Presence of tophi (yes/no), n (%) 116 (21.40) – –
Systolic blood pressure (mm Hg) (mean±SD) 139.90 (±20.55) 136 (±17.64) 0.039
Diastolic blood pressure (mm Hg) (mean±SD) 80.40 (±11.83) 80.00 (±9.62) 0.559
Telomere length (total leucocytes) (mean±SD) 5924.90 (±8617.76) 8242.70 (±8482.00) 0.0001
The data are presented as mean±SD. The significance of the association between the two classified subgroups of gout and healthy participants was tested using Fisher’s exact test
(categorical values) and Mann-Whitney U test (non-parametrical continues values) (p<0.05).
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Treatment might inhibit inﬂammation-induced telomere
erosion in immune cells of patients with gout
Since the majority of patients with gout were receiving anti-
inﬂammatory and/or urate-lowering treatment, we tested if any
treatment had any effect on the extent of telomeres. The treatment
included allopurinol (mean 200 mg/day), colchicine, corticoster-
oids, non-steroidal anti-inﬂammatory drugs or a combination of
these drugs. There was no signiﬁcant difference between TL of
treated (TL(±SD)=2301±2333.79) and untreated patients (TL
(±SD)=2998±5166.92) (N=23) (p=0.584). The insigniﬁcant
difference in TL might be due to low number of untreated
patients. Since the patients were treated with more than one drug,
any drug speciﬁc effect on the extent of TL was intractable.
Telomere shortening is not speciﬁc for certain immune
cell subsets
To identify immune cells with a dominant effect on the complica-
tions associated with senescence, we investigated the percentage
and TL of mononuclear cell subsets of 10 healthy participants
and 10 patients with gout (see online supplementary table S3).
In patients with gout, there were no signiﬁcant differences in
CD4+ T lymphocytes (24.42%), CD8+ cytotoxic T lympho-
cytes (6.74%), CD19+ B lymphocytes (7.02%), CD14+ mono-
cytes (7.75%), NK cells (7.92%) and CD123+/CD304+ pDCs
(0.02%) of patients with gout compared with healthy partici-
pants’ cell subsets that were 33.19% (p=0.11), 8.98%
(p=0.061), 10.07% (p=0.157), 6.28% (p=0.90), 7.38%
(p=0.52) and 0.11% (p=0.8) respectively (Mann-Whitney U
test, p<0.05).
Moreover, CD19+ B lymphocytes of patients with gout had
the longest telomeres and CD123+/CD304+ pDCs the shortest.
The longest and shortest telomeres in healthy participants were
also respectively in CD19+ B lymphocytes and CD123+/
CD304+ pDCs. In direct comparison between cell subsets from
patients with gout and healthy individuals, we did not observe a
signiﬁcant difference in TL.
Figure 2 Log-transformed leucocytes’ telomere length (kbp) of
pooled Dutch and New Zealand patients with gout and healthy
participants stratiﬁed according to (A) cardiovascular disease (CVD)
(yes/no) and (B) the level of creatinine (mmol/L). (A) Leucocytes’
telomere length of patients with gout (N=325) and healthy participants
(N=183) without (–) or with (+) (N gout=294) (N healthy
participant=383) CVD (chronic heart disease, non-fatal stroke, non-fatal
myocardial infarction and angina pectoris) is represented. (B)
Leucocytes’ telomere length of patients with gout and healthy
participants stratiﬁed according to the plasma level of creatinine
(mmol/L). The threshold of plasma creatinine was set at 100 mmol/L
and below the threshold, creatinine levels of patients with gout and
healthy participants are represented as normal (ﬁlled/empty bullets)
and subsequently above the threshold are represented as high. (N gout
normal creatinine=219) (N gout high creatinine =214) (N HC normal
creatinine =208) (N HC high creatinine =92). Box plot is represented
with minimum and maximum range. Statistical differences were tested
using Mann-Whitney U test (*p<0.05 was considered as signiﬁcant).
Figure 1 Log-transformed telomere length (kbp) of PBMCs of
patients with gout and healthy participants consistent with age (years).
Patients with gout (ﬁlled dots) (N=619) have shorter telomeres at
young age and the telomere length remains short in older patients with
gout (p=0.001). Young healthy participants (empty dots) (N=566)
represent longer telomere compared with older individuals (p<0.0001).
Overall telomere length of patients with gout is signiﬁcantly shorter
compared with healthy participants (p<0.0001). Statistical analysis
between the two groups was performed using two-tailed Student’s
t-test (Mann–Whitney correction). Correlation between telomere length
and age was tested through linear regression model.
Table 2 Multiple linear regression models for telomere length (TL)
measurements in patients and healthy participants
Number of
participants Standardised β SE p Value
A
Gout 619 −0.23 0.01 0.008
Cardiovascular disease 313 −0.19 0.02 0.023
Heart failure 134 −0.22 0.01 0.010
B
Cardiovascular disease 270 −0.55 0.02 0.001
Myocardial infarction (non-fatal) 70 −0.40 0.01 0.016
Mean±SD Standardised β SE p Value
C
Multiple number of flares 8.75±12.67 −0.30 2.02 0.005
Age at the first attack 51.12±16.75 −0.05 0.71 0.040
Disease duration 12.90±12.28 −0.22 0.52 0.035
(A) demonstrates the variables significantly associated with TL involving patients with
gout and healthy individuals assessed using multiple linear regression model. Age,
gender, smoking, cardiovascular disease, heart failure, stroke (non-fatal), myocardial
infarction (non-fatal), angina pectoris, systolic and diastolic blood pressure, body mass
index (kg/m2), serum UA level (mmol/L) and creatinine level (mmol/L) were included in
the model as independent variables (p<0.05).
(B) includes the results of multiple linear regression analysis associating TL with
cardiovascular events (heart failure, stroke (non-fatal), myocardial infarction (non-fatal),
angina pectoris and age) only in individuals with gout (p<0.05).
(C) represents multiple linear regression analysis results where the association between
TL and gout hallmarks (attack frequency, age at the first attack, disease duration, serum
UA level (mmol/L), creatinine level (mmol/L)) was tested (p<0.05).
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Telomerase activity is similar in patients with gout and
healthy participants
There was no correlation between hTERT gene expression level
and TL in total PBMCs. There was no signiﬁcant difference in
the mean fold change of hTERT expression level of patients
with gout (p=0.921, R2=0.013) and healthy participants
(p=0.087, R2=−0.264) (ﬁgure 3). Similarly, there was no cor-
relation between hTERT gene expression level and TL of the
immune cell subset (see online supplementary table S3).
DISCUSSION
In this study, we show that patients with gout have shorter telo-
meres than healthy participants, reﬂecting increased cellular sen-
escence. Telomere shortening was strongly associated with the
number of gouty ﬂares. Both gout and cardiovascular disease
were independently associated with shorter telomeres. This is to
our knowledge the ﬁrst study to show telomere erosion in
patients with gout compared with healthy participants.
There are several strengths of this study that minimise the risk
of chance observation or population bias. We exploited an inde-
pendent replication cohort where DNA material was isolated and
measured using a similar protocol. We observed intriguing TL
differences in participants of both Dutch and New Zealand
cohorts. It has been described previously that there are large dif-
ferences in TL between Caucasians from different European
descent. For instance, telomeres of inhabitants from Belgium
have been shown to be sixfold longer compared with inhabitants
from Italy and are approximately twice as long as inhabitants
from the UK, Ireland and Scotland.19 20 Since the Caucasians
from New Zealand have ancestors primarily from Britain and the
Dutch are more closely related to the Belgians, our ﬁndings are
most likely caused by an ancestral difference.20–22
To rule out an effect of differences in telomere maintenance
between patients with gout and healthy participants, we tested
hTERT gene expression, which has been shown to be a reliant
proxy marker to measure telomerase activity.22 We assessed
hTERT gene expression in PBMCs and cell subsets of patients
with gout and healthy individuals. We did not observe any dif-
ference in hTERT gene expression level that underscores any
bias due to telomerase activity as very unlikely. To minimise
technical issues, we used the same protocols and same machines
to measure TL.
To elucidate more details on underlying facets contributing to
telomere attrition in gout, we quantiﬁed absolute TL in CD4+
and CD8+ T cells, CD19+ B cells, CD14+ monocytes, NK cells
and pDCs in patients with gout and matched healthy partici-
pants. TL of CD4+ and CD8+ T cells, CD19+ B cells, CD14+
monocytes, NK cells and pDCs showed no signiﬁcant differ-
ence. In immune cell-subtypes of patients with gout, telomere
shortening showed a slightly declining trend compared with
healthy participants. However, the number of included partici-
pants is insufﬁcient to empower us to draw deﬁnite conclusions
from these results. Multiple research groups have corroborated
a strong link between chronic inﬂammation and decrease of TL
in cell subsets. For instance, studies on HIV elucidated the link
between chronic infection and telomere attrition in CD4+ and
CD8+ T cells.23 24 The replicative senescence of T lymphocytes
is not limited to HIV since it is broadly investigated in associ-
ation with malignancies,25 autoimmune disorders26 and envir-
onmental mediators.27 28 In autoimmune diseases, telomere
erosion in lymphocytes has been less well delineated. Telomere
erosion in CD14+ monocytes, however, was shown to be signiﬁ-
cantly associated with pro-inﬂammatory behaviour and, of high
relevance for our ﬁndings, thereby accelerated atherosclerotic
plaque formation.29 In the elderly, diminished NK cell function
was signiﬁcantly associated with the extent of telomere
erosion.30 31 The literature describing telomere attrition in
pDCs is rather poor and requires additional investigations.
Taken together, it is known from the literature that TL of
various immune cell subsets can be impacted when chronic or
recurrent inﬂammation is present. In our study, we could not
pinpoint a single cell subset responsible for the shortening of
telomeres as observed in the PBMCs from the gout population.
Since the effects on TL difference in PBMCs only came appar-
ent in a large cohort with hundreds of patients, we believe that
our lack of ﬁndings is most likely caused by a lack of power in
the subset analyses. On the other hand, since we observe such
similar ﬁndings between subsets, it seems to indicate that there
is not one single cell subset responsible for a large effect on TL
in the whole PBMC population. The latter might point to a
more generalisable effect in the cell subset populations.
Additionally, the shifting of naive T lymphocytes towards a
memory-like subset remains to be delineated whereby the CD28
marker repertoire might be indicative of chronic
inﬂammation-induced activation in T lymphocytes.32
We conclude that the shorter telomeres observed in the gout
population are most likely caused by increased PBMCs turnover
due to ongoing or frequent inﬂammatory episodes. This is con-
sistent with association of reduced TL with increased ﬂare fre-
quency. In various tissues and cell-subtypes, accelerated cell
turnover is inversely associated with replicative senescence. In
disorders involving accelerated oxidative injury and chronic
immune system activation as the main manifestation, such as sys-
temic lupus erythematosus,33 rheumatoid arthritis32 and sys-
temic sclerosis,34 enhanced cell turnover and telomere erosion
has been extensively described. Furthermore, we observed no
signiﬁcant TL difference in treated patients with gout compared
with patients without treatment. In addition, patients with the
most frequent ﬂares had the shortest telomeres. This might
indirectly imply a modulating effect of inﬂammation on TL and
thereby replicative senescence.
Figure 3 Log human telomerase reverse transcriptase (hTERT) gene
expression level (FC) of Dutch patients with gout, measured using
PBMCs’ RNA and quantitative PCR method. hTERT gene expression
levels between patients with gout (N=64) and healthy participants
(N=89) are not signiﬁcant (statistical differences were tested using
Mann-Whitney U test) (*p<0.05 was considered as signiﬁcant). Error
bars represent box plot with minimum and maximum range.
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The results of our study underline the strong association
between inﬂammation, senescence and cardiovascular disease, as
suggested previously.35 Recently, it has become apparent that
rheumatic diseases confer risk of cardiovascular disease develop-
ment. In rheumatoid arthritis, this risk approaches the risk of
patients with diabetes.36 The pathogenesis of this increased risk
is largely enigmatic, but is proposed to arise from a chronic
inﬂammatory environment, causing vascular damage and plaque
formation.37 38 The occurrence of atherosclerotic plaques has
been related to an increasing chronological age.11 On the other
hand, there is a large role for biological ageing as well, which
has been demonstrated by the inﬂux of pro-inﬂammatory senes-
cent immune cells in the plaque contributing to plaque instabil-
ity and rupture and eventually cardiovascular and
cerebrovascular events.39 The connection between replicative
senescence and the presence of cardiovascular disease has been
described before in the literature.40 Likewise, the prevalence of
MI in the elderly with shorter leucocytes’ TL is about three
times higher.40–42 A recent systemic review conﬁrmed this asso-
ciation by combining the telomere data and vascular morbidity
of >50 000 individuals.10
In summary, we present decreased TL as a feature of gout and
conﬁrm TL as an independent factor associated with ﬂare fre-
quency and cardiovascular disease. These data suggest that
intensive treatment of gout may prevent replicative senescence
and subsequently reduce the associated cardiovascular risk.
However, large prospective studies are needed to test this
possibility.
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Supplementary figures and tables 
Figure 1. Log transformed telomere length (kbp) of PBMCs of patients with gout and 
healthy individuals participating in Dutch cohort consistent with age (years). Patients with 
gout (N=145) have shorter telomeres at young age and the TL remains short in older patients with 
gout (P>0.05). Young healthy participants (N=273) represent longer telomere as compared to 
older individuals (P<0.0001). Overall TL of patients with gout is significantly shorter as compared 
to healthy participants (P<0.0001). Statistical analysis between the two groups was performed 
using two tailed Student T-test (Mann-Whitney correction). Correlation between TL and age was 
tested through linear regression model. 
2 
Figure 2. Log transformed telomere length (kbp) of PBMCs of patients with gout and 
healthy individuals participating in New Zealand cohort consistent with age (years). 
Patients with gout (N=474) have shorter telomeres at young age and the TL remains short in older 
patients with gout (P=0.001). Young healthy participants (N=293) represent longer telomere as 
compared to older individuals (P<0.0001). Overall TL of patients with gout is significantly shorter 
as compared to healthy participants (P<0.0001). Statistical analysis between the two groups was 
performed using two tailed Student T-test (Mann-Whitney correction). Correlation between TL 
and age was tested through linear regression model. 
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Supplementary files, table 1. Baseline characteristics of patients with gout and healthy 
participants in the Dutch cohort. 
  Gout (n=145)  Healthy participants (n=273) P Value 
Male n (%) 91 (62.76)  190 (69.70)  0.0001 
Age   63 ± 9.85 62 ± 14.11 0.0001 
Telomere length (total PBMC) 11215.33 ± 8042.54 18014.77 ± 9548.66 0.0001 
The data are presented as mean ± SD. The significance of the association between the 2 classified subgroups of 
patients with gout and healthy individuals was tested using Fisher's exact test (categorical values) and Mann–
Whitney U test (non-parametrical continues values) (P<0.05).  
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Supplementary files, table 2. Baseline characteristics of patients with gout and healthy 
participants in the New Zealand cohort. 
  Gout (n=474)  Healthy participants (n=293) P Value 
Male n (%) 388 (81.86)  233 (85.35)  0.0001 
Age  64 ± 12.82 55 ± 16.59 0.0001 
Telomere length (total PBMC) 2524.55 ± 3478.42 5151.93 ± 7674.79 0.0001 
The data are presented as mean ± SD. The significance of the association between the 2 classified subgroups of 
patients with gout and healthy individuals was tested using Fisher's exact test (categorical values) and Mann–
Whitney U test (non-parametrical continues values) (P<0.05).  
 5 
Supplementary files, table 3. Baseline characteristics of patients with gout and healthy 
participants in immune cell-subsets. 
 Gout (n=10) 
Healthy participants 
(n=11) 
P 
Value 
Male n (%) 8 (80)  10 (91)  >0.05 
Age (mean ± SD) 59 ± 16.27 45 ± 12.88 >0.05 
Age at the first flare (mean ± SD) 53 ± 5.76 - - 
Disease duration (year) (mean ± 
SD) 
5.70 ± 2.77 - - 
Colchicine (yes) n (%) 2 (20) N.A. - 
NSAID (yes) n (%) 1 (10) N.A. - 
Allopurinol (yes) 3 (30)  N.A. - 
(mean 200mg/day) n (%)    
Corticosteroids(yes) n (%) 2 (20)  N.A. - 
CVD (yes/no) n (%) 6 (60) N.D. - 
Diabetes (type 2) (yes) n (%) 6 (60) N.D. - 
Hypertension (yes) n (%) 4 (40) N.D. - 
Creatinine level (µmol/L) (mean 
± SD) 
109.00 (± 25.09) N.D. - 
BMI (kg/m2) mean (SD) (mean ± 
SD) 
32.58 (± 8.51) N.D. - 
Smoking (yes) n (%) 1 (10.00) N.D. - 
Serum urate (mmol/L) mean 
(SD) 
0.54 (±0.14) N.D. - 
Number of flares (mean ± SD) 19.70 ± 6.63 N.A. - 
Presence of tophi (yes) n (%) 4 (40) N.A. - 
Systolic blood pressure mean  121.00 (±21.81) N.D. - 
(mm Hg) (SD)    
Diastolic blood pressure mean  70.20 (±12.04) N.D. - 
(mm Hg) (SD)    
Telomere length CD3+/CD4+ 
(mean ± SD) 
15247.68 ± 13956.01 7339.70 ± 5063.97 >0.05 
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Telomere length CD3+/CD8+ 
(mean ± SD) 
13036.82 ± 7838.27 6987.34 ± 5666.97 >0.05 
Telomere length CD19+/CD20- 
(mean ± SD) 
23374.06 ± 25676.88 8620.14 ± 6476.89 >0.05 
Telomere length CD14+/CD16- 
(mean ± SD) 
10988.64 ± 4523.27 6864.43 ± 5103.57 >0.05 
Telomere length CD3-/CD56+ 
(mean ± SD) 
12599.09 ± 27954.54 5310.30 ± 1747.49 >0.05 
Telomere length 
CD123+/CD304+ (mean ± SD) 
2804.35 ± 2536.15 4052.95 ± 4776.86 >0.05 
hTERT CD3+/CD4+ (mean ± SD) 0.00112 ± 0.000240 0.00068 ± 0.000130 >0.05 
hTERT CD3+/CD8+ (mean ± SD) 0.00028 ± 0.000040 0.00036 ± 0.000100 >0.05 
hTERT CD19+/CD20- (mean ± 
SD) 
0.00039 ± 0.000054 0.00139 ± 0.001120 >0.05 
hTERT CD14+/CD16- (mean ± 
SD) 
0.00018 ± 0.000041 0.00004 ± 0.000020 >0.05 
hTERT CD3-/CD56+ (mean ± SD) 0.00030 ± 0.000001 0.00012 ± 0.000080 >0.05 
hTERT CD123+/CD304+ (mean ± 
SD) 
N.D. N.D. - 
The data are presented as mean ± SD. The significance of the association between the 2 classified subgroups of 
patients with gout and healthy participants was tested using Fisher's exact test (categorical values) and Mann–
Whitney U test (non-parametrical continues values) (P<0.05) (N.D.=not defined, N.A.=not applicable).  
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Supplementary files, table 4. Telomere length differences between gout participants with or 
without cardiovascular disease (A) and the association of cardiovascular disease with the flare 
frequency in the gout population (B). 
  
A) Telomere length (bp) in gout population 
with or without cardiovascular disease 
B) Multivariate linear regression on 
flare frequency and cardiovascular 
diseases in gout population 
  Yes (SD) No (SD) P Value Standardized β 
Standard 
error 
P 
Value 
Cardiovascular 
disease 
2187 
(±1934.10) 
6154 
(±8938.23) 
0.0001 
-1.35 
1.82 0.459 
Angina pectoris 
2223 
(±2625.17) 
5527 
(±7805.88) 
0.0001 
-2.94 3.07 
0.340 
Heart failure 
4656 
(±28288.80) 
13712 
(±28141.32) 
0.015 
-3.28 2.57 
0. 203 
Myocardial 
infarction 
2165 
(±2397.07) 
7272 
(±10916.47) 
0.0001 
-4.50 2.62 
0. 063 
Stroke 2182 (±2378.78) 
4784 
(±8980.58) 
0.0001 
-3.32 2.83 
0.242 
Telomere length (SD) in patients with gout with cardiovascular disease, angina pectoris, heart failure, myocardial 
infarction (non-fatal) and stroke (non-fatal) as concomitant disorders. A) The significance of the association between 
the 2 classified subgroups of gout participants was tested using Mann–Whitney U test. B) The association between 
the same variables (cardiovascular comorbidities) and the flare frequency was tested in a multiple variable linear 
regression model (P<0.05).  
 8 
Supplementary files, table 5. The effect of additional co-variables on telomere length of 
patients with gout and healthy participants separately. 
  Gout Healthy participant 
 
Correlation 
Coefficient 
(R2) P value 
Correlation 
Coefficient 
(R2) P value 
Gender -0.023 0.574 0.173 0.001 
Age (years) -0.102 0.014 -0.315 0.0001 
Smoking (yes/no) 0.418 0.0001 -0.041 0.669 
BMI 0.031 0.459 0.080 0.175 
Creatinine (mol/L) -0.205 0.0002 -0.203 0.001 
The statistical significance of the data is tested using two-tailed Spearman’s bivariate correlation (P<0.05). 
 
 
